Read More

Viridian Therapeutics Appoints Stephen Mahoney As New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs And Announces $185M Private Placement Financing

– Stephen Mahoney appointed President and Chief Executive Officer –– Potential best-in-class subcutaneous and intravenous thyroid eye disease (TED) programs targeting insulin-like growth factor 1 receptor (IGF-1R) remain

VRDN